Balyasny Asset Management
CYTK icon

Balyasny Asset Management’s Cytokinetics CYTK Stock Holding History

Balyasny Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.6M Sell
711,676
-280,869
-28% -$20.2M 0.08% 311
2026
Q1 		$65.4M Buy
+992,545
New +$63.1M 0.08% 268
2024
Q4 		– Sell
-117,487
Closed -$6.2M – 2843
2024
Q3 		$6.2M Sell
117,487
-483,880
-80% -$27M 0.01% 1176
2024
Q2 		$32.6M Sell
601,367
-73,695
-11% -$4.45M 0.06% 436
2024
Q1 		$47.3M Buy
675,062
+261,925
+63% +$20.3M 0.08% 315
2023
Q4 		$34.5M Sell
413,137
-765,741
-65% -$27.7M 0.06% 387
2023
Q3 		$34.7M Buy
1,178,878
+107,346
+10% +$3.58M 0.07% 379
2023
Q2 		$35M Buy
1,071,532
+119,528
+13% +$4.42M 0.08% 354
2023
Q1 		$33.5M Buy
952,004
+70,596
+8% +$2.88M 0.08% 339
2022
Q4 		$40.4M Buy
881,408
+598,160
+211% +$25.7M 0.11% 230
2022
Q3 		$13.7M Buy
283,248
+94,609
+50% +$4.55M 0.04% 554
2022
Q2 		$7.41M Buy
+188,639
New +$7.59M 0.02% 767
2022
Q1 		– Sell
-9,911
Closed -$452K – 2540
2021
Q4 		$452K Sell
9,911
-27,004
-73% -$1.04M ﹤0.01% 1641
2021
Q3 		$1.32M Buy
+36,915
New +$1.09M 0.01% 1260
2020
Q4 		– Sell
-125,298
Closed -$2.71M – 1396
2020
Q3 		$2.71M Buy
+125,298
New +$2.93M 0.02% 761
2018
Q1 		– Sell
-19,877
Closed -$162K – 2003
2017
Q4 		$162K Sell
19,877
-822,118
-98% -$9.33M ﹤0.01% 1935
2017
Q3 		$12.2M Buy
841,995
+210,195
+33% +$2.87M 0.05% 440
2017
Q2 		$7.64M Buy
631,800
+124,300
+24% +$1.73M 0.03% 623
2017
Q1 		$6.52M Buy
507,500
+181,925
+56% +$2.13M 0.03% 625
2016
Q4 		$3.96M Buy
+325,575
New +$3.46M 0.02% 746
2016
Q2 		– Sell
-176,559
Closed -$1.25M – 1213
2016
Q1 		$1.25M Sell
176,559
-55,871
-24% -$408K 0.01% 745
2015
Q4 		$2.43M Buy
+232,430
New +$2.28M 0.02% 626

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management's CYTK Position: Q2 2026 in Review

Balyasny Asset Management reduced its Cytokinetics (CYTK) stake by 28% in Q2 2026, selling an estimated $20.2M and leaving 711,676 shares worth $60.6M. The position accounts for 0.08% of the portfolio, ranked #311.

Balyasny Asset Management first reported a position in CYTK in Q4 2015 and has held it in 22 quarters since. The position peaked at $65.4M in Q1 2026. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Balyasny Asset Management held 711,676 shares of Cytokinetics worth $60.6M as of Q2 2026.
  • Balyasny Asset Management sold 280,869 Cytokinetics shares in Q2 2026, an estimated $20.2M.
  • Cytokinetics made up 0.08% of Balyasny Asset Management's portfolio in Q2 2026, its #311 holding.
  • Balyasny Asset Management first reported a position in Cytokinetics in Q4 2015 and has held it in 22 quarters since.
  • Balyasny Asset Management's Cytokinetics position peaked at $65.4M in Q1 2026.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.